No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AUTL240517P7500
- 3.21
- 0.000.00%
15min DelayTrading Apr 18 10:36 ET
0.00High0.00Low
0.00Open3.21Pre Close0 Volume2 Open Interest7.50Strike Price0.00Turnover484.65%IV-9.87%PremiumMay 17, 2024Expiry Date3.40Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.6643Delta0.1186Gamma1.08Leverage Ratio-0.0666Theta-0.0013Rho-0.72Eff Leverage0.0023Vega
Intraday
- 5D
- 1D
News
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Wednesday morning, rising 0.34% to 1,399.71 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.24% to 1,364.10 on the S&P Europe Select ADR Index. From continental Europe,
Abstract for Longer-term Follow-up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obe-cel for Adult R/r B-ALL Selected for an Oral Presentation at ASCO
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Comments
Several highly anticipated PDUFA decisions are approaching..👇
Abeona Therapeutics ( $Abeona Therapeutics(ABEO.US$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals(RCKT.US$ )...
Abeona Therapeutics ( $Abeona Therapeutics(ABEO.US$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals(RCKT.US$ )...
7
The appointment of Robert W. Azelby, with his extensive experience and track record in building successful biotech companies, is seen as a valuable addition to Autolus's Board as the company moves closer to commercializing its first product.
Read more